Assessing genetic variations in patients with neuromyelitis optica and multiple sclerosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the frequency of genetic polymorphisms in the FCGR3A gene among Italian patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and multiple sclerosis (MS). Adult patients from various clinical centers in the Lazio region will be selected, and their medical records will be analyzed for clinical and neuroimaging data. A blood sample will be collected from each participant to assess the genetic variations that may influence disease pathology and immune response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients diagnosed with MS, NMOSD, or MOGAD receiving care at participating centers
* Patients aged ≥ 18 years
* Ability to understand and sign informed consent

Exclusion Criteria:

* Individuals under 18 years of age
* Inability to provide informed consent

Where it's running

• Fondazione Policlinico Universitario Agostino Gemelli IRCCS
  Roma, Roma, Italy Recruiting

Study contacts

• Study coordinator: Massimiliano Mirabella, Neurology Associate Professor
• Email: massimiliano.mirabella@policlinicogemelli.it
• Phone: 0630155390

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using ultra-high field and metabolic MRI to understand resilience and degeneration in the aging and diseased brain

  This project will try advanced 3T and 7T MRI scans, including sodium and phosphorus imaging, to see if metabolic and connectivity changes explain resilience and degeneration in adults with MS, NMOSD, MOGAD, Alzheimer’s, Parkinson’s, or healthy aging.

  Recruiting Assistance Publique Hopitaux De Marseille · Marseille · NCT07202494

• Universal CD19/BCMA CAR T-cell therapy for relapsed or refractory neurological autoimmune diseases

  This will test whether a single infusion of universal CD19/BCMA CAR T-cells given after chemotherapy helps adults with relapsed or refractory neurological autoimmune diseases who have CD19- or BCMA-positive B cells.

  Recruiting Early Phase 1 Tianjin Huanhu Hospital · Tianjin · NCT06939166

• Investigating risk factors for disability progression in Multiple Sclerosis

  This study is trying to find out what factors might make disability get worse in people with Multiple Sclerosis by looking at their medical history and MRI scans.

  Recruiting Cedars-Sinai Medical Center · Los Angeles, California · NCT05204459

• Observational study of neuroinflammation diseases in China

  This study is trying to see how brain and spinal cord changes in people with neuroinflammatory diseases can help us understand their condition better over a year of MRI scans.

  Recruiting Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT04106830

• Treadmill-based virtual reality walking training for MS patients

  This study tests whether a treadmill with virtual reality and smart socks can help people with multiple sclerosis walk better and feel safer in daily life.

  Recruiting Shepherd Center, Atlanta GA · Atlanta, Georgia · NCT07927439

• Virtual Reality and Mental Practice to Improve Balance and Walking in Relapsing MS

  This study tests whether virtual reality training or mental practice can improve balance and walking in people with relapsing–remitting multiple sclerosis.

  Recruiting Cairo University · Giza, Giza Governorate · NCT07918339

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.